BMO reiterates Trevi Therapeutics stock rating after rival study fails
Covered in this story
What has happened since
- Trevi Therapeutics Inc is down 0.6% since this was published, 5 days ago.
Price move measured from the close nearest publication to the latest quote.
Tracked from this story
BMO Capital Markets’s $36 target on $TRVI is on the record and being tracked to Oct 2027 (12-month default), scored on the close that day.
BMO Capital Markets’s track record →Call it yourself
No member calls on $TRVI yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Trevi Therapeutics Inc →Summary aggregated from Investing.com's public RSS feed. The full reporting belongs to Investing.com — please read it on their site.